Refractory angina: new drugs on the block

References

• Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina. Report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23(5):355–370.
   PubMed Web of Science ®Google Scholar
• Andréll P, Ekre O, Grip L, et al. Fatality, morbidity and quality of life in patients with refractory angina pectoris. Int J Cardiol. 2011;147(3):377–382.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Broderick S, Anstrom KJ, et al. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc. 2015;4(2):e001287.
   PubMed Web of Science ®Google Scholar
• Henry TD, Satran D, Jolicoeur EM. Treatment of refractory angina in patients not suitable for revascularization. Nat Rev Cardiol. 2014;11(2):78–95.
   PubMed Web of Science ®Google Scholar
• Piciche M. Embolization of the internal thoracic arteries in refractory angina. Int J Cardiol. 2016;212:310.
   PubMed Web of Science ®Google Scholar
• Stoller M, De Marchi SF, Seiler C. Function of natural internal mammary-to-coronary artery bypasses and its effect on myocardial ischemia. Circulation. 2014;129(25):2645–2652.
   PubMed Web of Science ®Google Scholar
• Giannopoulos AA, Giannoglou GD, Chatzizisis YS. Pharmacological approaches of refractory angina. Pharmacol Ther. 2016;163:118–131.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354–e471.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
   PubMed Web of Science ®Google Scholar
• Vilaine JP. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res. 2006;53(5):424–434.
   PubMed Web of Science ®Google Scholar
• Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393–405.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–2536.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–548.
   PubMed Web of Science ®Google Scholar
• Giannoglou GD, Giannopoulos AA, Chatzizisis YS. Lowering heart rate post revascularization: angina and quality of life improvement. Angiology. 2016. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Zarifis J, Grammatikou V, Kallistratos M, et al. Antianginal efficacy of ivabradine in patients with history of coronary revascularization. Angiology. 2016. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–816.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–1099.
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(suppl 4):iv6–iv14.
   PubMedGoogle Scholar
• Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–2045.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032–2039.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48(3):566–575.
   PubMed Web of Science ®Google Scholar
• Belsey J, Savelieva I, Mugelli A, et al. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837–848.
   PubMed Web of Science ®Google Scholar
• Alexander KP, Weisz G, Prather K, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39–47.
   Google Scholar
• Bennett NM, Iyer V, Arndt TL, et al. Ranolazine refractory angina registry: 1-year results. Crit Pathw Cardiol. 2014;13(3):96–98.
   PubMedGoogle Scholar
• Yang EH, Barsness GW. Evolving treatment strategies for chronic refractory angina. Expert Opin Pharmacother. 2006;7(3):259–266.
   PubMed Web of Science ®Google Scholar
• Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;(4):CD003614.
   PubMed Web of Science ®Google Scholar
• Szwed H, Hradec J, Preda I. Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron Artery Dis. 2001;12(Suppl 1):S25–8.
   Google Scholar
• Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780–785.
   PubMed Web of Science ®Google Scholar
• Henry TD, Satran D, Hodges JS, et al. Long-term survival in patients with refractory angina. Eur Heart J. 2013;34(34):2683–2688.
   PubMed Web of Science ®Google Scholar